Halpan-D Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort associated with delayed gastric emptying or gastroparesis. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively reducing acid-related damage and promoting mucosal healing in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combination of these two agents in Halpan-D Capsule PR provides a synergistic effect, addressing both motility and acid secretion abnormalities commonly observed in upper gastrointestinal disorders. The prolonged-release formulation ensures sustained therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Halpan-D Capsule PR should be administered under medical supervision, with caution advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. It is contraindicated in individuals with gastrointestinal hemorrhage, mechanical obstruction, or prolactin-releasing pituitary tumors. Adverse effects may include headache, dry mouth, abdominal cramps, and rare extrapyramidal symptoms.